MapLight Therapeutics, Inc. (MPLT) Valuation

Valuation

Model-based estimates, not advice. The DCF is the discounted-cash-flow value per share; compare it with the price, not as a target.

DCF fair value

-86.3%

$0.93

vs $6.78 price

Levered DCF

$0.93

After debt service

Piotroski score

2 / 9

Weak

Altman Z-score

5.7

Safe zone

Rating

Overall 2 / 5

Ratios by fiscal year

Margins and yields are shares of revenue, equity or price; multiples are ×.

Metric	FY2025	FY2024	FY2023	FY2022
P/E	-4.8×	-9.81×	-13.69×	-25.47×
P/B	1.69×	6.6×	10.66×	36.41×
P/S	0×	0×	0×	0×
EV / EBITDA	-4.56×	-9.47×	-12.44×	-25.08×
Gross margin	0.0%	0.0%	0.0%	0.0%
Operating margin	0.0%	0.0%	0.0%	0.0%
Net margin	0.0%	0.0%	0.0%	0.0%
Current ratio	20.01×	7.2×	5.69×	2.54×
Debt / equity	0.01×	0.06×	0.08×	0.3×
Interest coverage	0×	0×	0×	0×
Dividend yield	0.0%	0.0%	0.0%	0.0%
Payout ratio	0.0%	0.0%	0.0%	0.0%

Key metrics by fiscal year

Metric	FY2025	FY2024	FY2023	FY2022
Return on equity	-35.2%	-67.3%	-78.2%	-143.8%
Return on invested capital	-36.4%	-68.1%	-74.2%	-115.1%
Return on assets	-33.6%	-56.7%	-60.9%	-76.2%
Free cash flow yield	-17.9%	-10.5%	-6.9%	-3.6%
Earnings yield	-20.8%	-10.2%	-7.3%	-4.0%
Enterprise value	$732.6M	$728.1M	$686M	$738.4M
Net debt / EBITDA	0.25×	0.41×	1.34×	0.73×
Cash conversion cycle (days)	0	-996	0	0